Role of CD68 in tumor immunity and prognosis prediction in pan-cancer

Abstract CD68 plays a critical role in promoting phagocytosis; however, the function of CD68 in tumor immunity and prognosis remains unknown. We analyzed CD68 expression among 33 tumor and normal tissues from The Cancer Genome Atlas and Genotype-Tissue Expression datasets. The relationship between C...

Full description

Bibliographic Details
Main Authors: Jingwei Zhang, Shuwang Li, Fangkun Liu, Kui Yang
Format: Article
Language:English
Published: Nature Portfolio 2022-05-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-022-11503-2
_version_ 1811253224262336512
author Jingwei Zhang
Shuwang Li
Fangkun Liu
Kui Yang
author_facet Jingwei Zhang
Shuwang Li
Fangkun Liu
Kui Yang
author_sort Jingwei Zhang
collection DOAJ
description Abstract CD68 plays a critical role in promoting phagocytosis; however, the function of CD68 in tumor immunity and prognosis remains unknown. We analyzed CD68 expression among 33 tumor and normal tissues from The Cancer Genome Atlas and Genotype-Tissue Expression datasets. The relationship between CD68 expression and cancer prognosis, immune infiltration, checkpoint markers, and drug response was explored. Upregulated CD68 levels were observed in various cancer types, which were verified through tumor tissue chips using immunohistochemistry. High levels of CD68 in tumor samples correlated with an adverse prognosis in glioblastoma, kidney renal clear cell carcinoma, lower-grade glioma, liver hepatocellular carcinoma, lung squamous cell carcinoma, thyroid carcinoma, and thymoma and a favorable prognosis in kidney chromophobe. The top three negatively enriched Kyoto Encyclopedia of Genes and Genomes terms in the high CD68 subgroup were chemokine signaling pathway, cytokine-cytokine receptor interaction, and cell adhesion molecule cams. The top negatively enriched HALLMARK terms included complement, allograft rejection, and inflammatory response. A series of targeted drugs and small-molecule drugs with promising therapeutic effects were predicted. The clinical prognosis and immune infiltration of high expression levels of CD68 differ across tumor types. Inhibiting CD68-dependent signaling could be a promising therapeutic strategy for immunotherapy in many tumor types.
first_indexed 2024-04-12T16:47:37Z
format Article
id doaj.art-045ab09015cd446a9267ee73a7664a25
institution Directory Open Access Journal
issn 2045-2322
language English
last_indexed 2024-04-12T16:47:37Z
publishDate 2022-05-01
publisher Nature Portfolio
record_format Article
series Scientific Reports
spelling doaj.art-045ab09015cd446a9267ee73a7664a252022-12-22T03:24:31ZengNature PortfolioScientific Reports2045-23222022-05-0112111310.1038/s41598-022-11503-2Role of CD68 in tumor immunity and prognosis prediction in pan-cancerJingwei Zhang0Shuwang Li1Fangkun Liu2Kui Yang3Department of Neurosurgery, Xiangya Hospital, Central South UniversityDepartment of Neurosurgery, Xiangya Hospital, Central South UniversityDepartment of Neurosurgery, Xiangya Hospital, Central South UniversityDepartment of Neurosurgery, Xiangya Hospital, Central South UniversityAbstract CD68 plays a critical role in promoting phagocytosis; however, the function of CD68 in tumor immunity and prognosis remains unknown. We analyzed CD68 expression among 33 tumor and normal tissues from The Cancer Genome Atlas and Genotype-Tissue Expression datasets. The relationship between CD68 expression and cancer prognosis, immune infiltration, checkpoint markers, and drug response was explored. Upregulated CD68 levels were observed in various cancer types, which were verified through tumor tissue chips using immunohistochemistry. High levels of CD68 in tumor samples correlated with an adverse prognosis in glioblastoma, kidney renal clear cell carcinoma, lower-grade glioma, liver hepatocellular carcinoma, lung squamous cell carcinoma, thyroid carcinoma, and thymoma and a favorable prognosis in kidney chromophobe. The top three negatively enriched Kyoto Encyclopedia of Genes and Genomes terms in the high CD68 subgroup were chemokine signaling pathway, cytokine-cytokine receptor interaction, and cell adhesion molecule cams. The top negatively enriched HALLMARK terms included complement, allograft rejection, and inflammatory response. A series of targeted drugs and small-molecule drugs with promising therapeutic effects were predicted. The clinical prognosis and immune infiltration of high expression levels of CD68 differ across tumor types. Inhibiting CD68-dependent signaling could be a promising therapeutic strategy for immunotherapy in many tumor types.https://doi.org/10.1038/s41598-022-11503-2
spellingShingle Jingwei Zhang
Shuwang Li
Fangkun Liu
Kui Yang
Role of CD68 in tumor immunity and prognosis prediction in pan-cancer
Scientific Reports
title Role of CD68 in tumor immunity and prognosis prediction in pan-cancer
title_full Role of CD68 in tumor immunity and prognosis prediction in pan-cancer
title_fullStr Role of CD68 in tumor immunity and prognosis prediction in pan-cancer
title_full_unstemmed Role of CD68 in tumor immunity and prognosis prediction in pan-cancer
title_short Role of CD68 in tumor immunity and prognosis prediction in pan-cancer
title_sort role of cd68 in tumor immunity and prognosis prediction in pan cancer
url https://doi.org/10.1038/s41598-022-11503-2
work_keys_str_mv AT jingweizhang roleofcd68intumorimmunityandprognosispredictioninpancancer
AT shuwangli roleofcd68intumorimmunityandprognosispredictioninpancancer
AT fangkunliu roleofcd68intumorimmunityandprognosispredictioninpancancer
AT kuiyang roleofcd68intumorimmunityandprognosispredictioninpancancer